Immunogenicity - implications for rheumatoid arthritis treatment

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Biologic agents for rheumatoid arthritis are immunogenic proteins, leading to antibody formation.
• Antibodies against biologic agents (AAB) can impact treatment efficacy and cause adverse events like infusion reactions.

Purpose of the Study:

• To highlight the clinical significance of AABs in rheumatoid arthritis management.
• To discuss strategies for managing patients with AABs and optimizing biologic therapy.

Main Methods:

• Review of existing literature on biologic agents and AABs in rheumatoid arthritis.
• Analysis of factors influencing AAB development and their clinical implications.

Main Results:

• AABs can lead to loss of efficacy and potential adverse events.
• Rising ANA titers or anti-dsDNA antibodies may indicate AAB emergence.
• Concurrent use of non-biologic DMARDs is crucial for preventing AABs.

Conclusions:

• Understanding AABs is vital for effective biologic agent selection and patient management.
• Monitoring for AABs and appropriate DMARD use can enhance long-term treatment success in rheumatoid arthritis.